Prenetics Global Limited is a health sciences company that has transitioned from a pure-play genomics and diagnostics firm into a consumer health and longevity business. Founded in 2014 and headquartered in Hong Kong, the company initially built its reputation through its CircleDNA consumer genetic testing brand and by providing extensive COVID-19 testing services. However, Prenetics recently executed a major strategic pivot to focus on the premium nutrition and dietary supplement market.
The company's core revenue driver is now IM8, a direct-to-consumer health and wellness brand co-founded with David Beckham. IM8 offers science-backed daily nutrition products, most notably an all-in-one powder supplement designed to replace multiple traditional supplements. Operating on a digitally native, subscription-first model, IM8 has experienced explosive growth, reaching over $100 million in annualized recurring revenue within its first year and shipping to over 40 countries. To concentrate resources on this rapidly scaling consumer brand, Prenetics divested its non-core clinical and diagnostic businesses, including ACT Genomics, Insighta, and the Europa sports nutrition distribution arm. As of early 2026, IM8 accounts for approximately 94% of the company's total revenue.
Financially, Prenetics has utilized the cash flows from its consumer health business and proceeds from its divestitures to fund global expansion and share repurchases. The company also gained attention for implementing a Bitcoin treasury strategy to hold digital assets on its balance sheet as a long-term reserve, though it discontinued future cryptocurrency purchases in late 2025. By shedding its capital-intensive clinical diagnostic units, Prenetics has repositioned itself as a high-growth player in the global consumer wellness and dietary supplement industry.
